The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion recommending against the granting of a marketing authorisation for Sumatriptan Galpharm intended as an over-the-counter medicine for the treatment of migraine attacks. Sumatriptan is a generic of Imigran.